NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of the world’s adult population. Several cohort studies have consistently documented that NAFLD (especially in its more advanced forms) is associated with a higher risk of all-cause mortality and that the leading causes of death among patients with NAFLD are cardiovascular diseases (CVDs), followed by extrahepatic malignancies and liver-related complications. A growing body of evidence also indicates that NAFLD is strongly associated with an increased risk of major CVD events and other cardiac complications (ie, cardiomyopathy, cardiac valvular calcification and cardiac arrhythmias), independently of traditional cardiovascular risk factors. This narrative review provides an overview of the literature on: (1) the evidence for an association between NAFLD and increased risk of cardiovascular, cardiac and arrhythmic complications, (2) the putative pathophysiological mechanisms linking NAFLD to CVD and other cardiac complications and (3) the current pharmacological treatments for NAFLD that might also benefit or adversely affect risk of CVD.
cardiovascular complications, cardiovascular disease, nonalcoholic steatohepatitis
1691-1705
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Tilg, Herbert
ef8597c1-ea86-4416-aa92-be76c96d65fa
1 September 2020
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Tilg, Herbert
ef8597c1-ea86-4416-aa92-be76c96d65fa
Targher, Giovanni, Byrne, Christopher and Tilg, Herbert
(2020)
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
Gut, 69 (9), .
(doi:10.1136/gutjnl-2020-320622).
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of the world’s adult population. Several cohort studies have consistently documented that NAFLD (especially in its more advanced forms) is associated with a higher risk of all-cause mortality and that the leading causes of death among patients with NAFLD are cardiovascular diseases (CVDs), followed by extrahepatic malignancies and liver-related complications. A growing body of evidence also indicates that NAFLD is strongly associated with an increased risk of major CVD events and other cardiac complications (ie, cardiomyopathy, cardiac valvular calcification and cardiac arrhythmias), independently of traditional cardiovascular risk factors. This narrative review provides an overview of the literature on: (1) the evidence for an association between NAFLD and increased risk of cardiovascular, cardiac and arrhythmic complications, (2) the putative pathophysiological mechanisms linking NAFLD to CVD and other cardiac complications and (3) the current pharmacological treatments for NAFLD that might also benefit or adversely affect risk of CVD.
Text
NAFLD and CVD risk GUT R1 clean copy R1 final
- Accepted Manuscript
Text
Online-only supplementary material
- Accepted Manuscript
Text
Figure 1 final
- Accepted Manuscript
Text
Figure 2_final
- Accepted Manuscript
Text
Figure 3_final
- Accepted Manuscript
Text
Figure 4_final
- Accepted Manuscript
Show all 6 downloads.
More information
Accepted/In Press date: 31 March 2020
e-pub ahead of print date: 22 April 2020
Published date: 1 September 2020
Additional Information:
Funding Information:
Acknowledgements CDB is supported in part by grants from the Southampton National Institute for Health Research Biomedical Research Centre. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. HT is supported by the excellence initiative VASCage (Centre for Promoting Vascular Health in the Ageing Community), an R&D K-Centre (COMET program - Competence Centers for Excellent Technologies) funded by the Austrian Ministry for Transport, Innovation and Technology, the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg and Vienna.
Publisher Copyright:
© 2020 Author(s) (or their employer(s)). Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords:
cardiovascular complications, cardiovascular disease, nonalcoholic steatohepatitis
Identifiers
Local EPrints ID: 439194
URI: http://eprints.soton.ac.uk/id/eprint/439194
ISSN: 1468-3288
PURE UUID: 7931cd67-a4d8-4a39-b468-5b63f0ce787e
Catalogue record
Date deposited: 06 Apr 2020 16:36
Last modified: 17 Mar 2024 05:27
Export record
Altmetrics
Contributors
Author:
Giovanni Targher
Author:
Herbert Tilg
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
